Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation.

abstract：:Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overa...

journal_title：Hematological oncology

authors： Thompson CA,Yost KJ,Maurer MJ,Allmer C,Farooq U,Habermann TM,Inwards DJ,Macon WR,Link BK,Rosenthal AC,Cerhan JR

更新日期：2018-12-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14)(q13;q32) CCND1/IGH translocation. This lymphoma is however extremely heterogeneous in terms of molecular alterations. Moreover, the course of the disease can vary greatly between indolent forms with slow progression and aggressi...

journal_title：Hematological oncology

authors： Le Bris Y,Magrangeas F,Moreau A,Chiron D,Guérin-Charbonnel C,Theisen O,Pichon O,Canioni D,Burroni B,Maisonneuve H,Thieblemont C,Oberic L,Gyan E,Pellat-Deceunynck C,Hermine O,Delfau-Larue MH,Tessoulin B,Béné MC,Minviel

更新日期：2020-10-01 00:00:00

abstract：:Acute myeloid leukaemia (AML) is a clinically aggressive disease with marked genetic heterogeneity. Cytogenetic abnormalities provide the basis for risk stratification into clinically favourable, intermediate, and unfavourable groups. There are additional genetic mutations, which further influence the prognosis of pat...

journal_title：Hematological oncology

authors： Mughal MK,Akhter A,Street L,Pournazari P,Shabani-Rad MT,Mansoor A

更新日期：2017-09-01 00:00:00

abstract：:Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational stud...

journal_title：Hematological oncology

authors： Klener P,Fronkova E,Belada D,Forsterova K,Pytlik R,Kalinova M,Simkovic M,Salek D,Mocikova H,Prochazka V,Blahovcova P,Janikova A,Markova J,Obr A,Berkova A,Kubinyi J,Vaskova M,Mejstrikova E,Campr V,Jaksa R,Kodet R,

更新日期：2018-02-01 00:00:00

abstract：:Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...

journal_title：Hematological oncology

authors： Zamkoff KW,Watman NP,Duggan DB,Poiesz BJ,Gottlieb AJ

更新日期：1990-03-01 00:00:00

abstract：:Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese wi...

journal_title：Hematological oncology

authors： Qin S,Fan L,Liang J,Gale R,Miao Y,Wu Y,Wang R,Yang H,Wu W,Xia Y,Wu J,Zhu H,Wang L,Xu W,Li J

更新日期：2018-10-01 00:00:00

abstract：:Sixty-five cases of malignant lymphoma of the nose, paranasal sinuses and hard palate were retrospectively analysed to identify the presence or absence of angiocentric lesions. We observed that the 23 patients with angiocentric lesions had a worse prognosis with a shorter duration of response and also a shorter durati...

journal_title：Hematological oncology

authors： Aviles A,Rodriguez L,Guzman R,Talavera A,Garcia EL,Diaz-Maqueo JC

更新日期：1992-05-01 00:00:00

abstract：:Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...

journal_title：Hematological oncology

authors： Tonialini L,Bonfichi M,Ferrero S,Malipiero G,Nozza A,Argnani L,Zinzani PL

更新日期：2018-10-01 00:00:00

abstract：:There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...

journal_title：Hematological oncology

authors： Andriani A,Elli E,Trapè G,Villivà N,Fianchi L,Di Veroli A,Niscola P,Centra A,Anaclerico B,Montanaro G,Martini V,Aroldi A,Carmosino I,Voso MT,Breccia M,Montanaro M,Foà R,Latagliata R

更新日期：2019-08-01 00:00:00

abstract：:In the last four years we established five long term cultures from tumor material of Hodgkin's disease. The in vitro cells have malignant characteristics and represent the in vivo H- and SR-cells. Common immunological, functional and morphological assays did not characterize the in vitro cells to be a known cell type ...

journal_title：Hematological oncology

authors： Diehl V,Burrichter H,Schaadt M,Kirchner HH,Fonatsch C,Stein H,Gerdes J,Heit W,Ziegler A

更新日期：1983-04-01 00:00:00

abstract：:Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...

journal_title：Hematological oncology

authors： Sekine L,Morais VD,Lima KM,Onsten TG,Ziegelmann PK,Ribeiro RA

更新日期：2015-12-01 00:00:00

abstract：:Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular monitoring of BCR-ABL tra...

journal_title：Hematological oncology

authors： Martinelli G,Iacobucci I,Soverini S,Cilloni D,Saglio G,Pane F,Baccarani M

更新日期：2006-12-01 00:00:00

abstract：:A retrospective study of 163 patients with Hodgkin's disease treated between 1969 and 1987 was performed to identify adverse prognostic factors. One hundred and thirty-five patients (83 per cent) attained a complete remission and 42 (31 per cent) of these have relapsed (median follow-up--43 months). Using multivariate...

journal_title：Hematological oncology

authors： Jeffery GM,Colls BM,Robinson BA,Fitzharris BM,Atkinson CH

更新日期：1989-09-01 00:00:00

abstract：:Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...

journal_title：Hematological oncology

authors： Sorigue M,Mercadal S,Alonso S,Fernández-Álvarez R,García O,Moreno M,Pomares H,Alcoceba M,González-García E,Motlló C,González-Barca E,Martin A,Sureda A,Caballero D,Ribera JM,Sancho JM

更新日期：2017-12-01 00:00:00

abstract：:Fungal infection is a serious complication in immunocompromised patients, especially those with neutropenia. Itraconazole (ITZ) is expected to be an effective prophylactic agent for fungal infection because it has more activity against Aspergillus species than fluconazole and it is less toxic than amphotericin-B. Howe...

journal_title：Hematological oncology

authors： Kanda Y,Kami M,Matsuyama T,Mitani K,Chiba S,Yazaki Y,Hirai H

更新日期：1998-03-01 00:00:00

abstract：:Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-ho...

journal_title：Hematological oncology

authors： Solán L,Landete E,Bailén R,Dorado N,Oarbeascoa G,Anguita J,Díez-Martín JL,Kwon M

更新日期：2020-10-01 00:00:00

abstract：:Smoking has been identified as a significant risk factor for acute myeloid leukaemia (AML). However, epidemiological evidence for the effect of smoking on the risk of AML among Asians is scarce. Here, we investigated the impact of smoking habits on the risk of AML by conducting a pooled analysis of 9 population-based ...

journal_title：Hematological oncology

authors： Ugai T,Matsuo K,Oze I,Ito H,Wakai K,Wada K,Nagata C,Nakayama T,Liu R,Kitamura Y,Tamakoshi A,Tsuji I,Sugawara Y,Sawada N,Sadakane A,Tanaka K,Mizoue T,Inoue M,Tsugane S,Shimazu T,Research Group for the Development a

更新日期：2018-02-01 00:00:00

abstract：:Plasma cholesterol concentrations were determined in 83 acute myeloid leukemia patients. Mean plasma cholesterol concentration (+/- S.D.) at the time of diagnosis was 2.91 mmol/L (+/- 1.13). The percentage of AML patients having hypocholesterolemia was 90.4 per cent. The lowest cholesterol levels were observed in the ...

journal_title：Hematological oncology

authors： Zyada LE,Hassan HT,Rees JK,Ragab MH

更新日期：1990-01-01 00:00:00

abstract：:Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...

journal_title：Hematological oncology

authors： Yu L,Chen K,Xu Y,Wang S,Liu Q,Ye Q,Ye T,Sun Y

更新日期：2017-09-01 00:00:00

abstract：:Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...

journal_title：Hematological oncology

authors： Kiesewetter B,Lamm W,Neuper O,Mayerhoefer ME,Simonitsch-Klupp I,Raderer M

更新日期：2019-10-01 00:00:00

abstract：:Bone marrow interstitial fluid (BMIF) has not been well characterized. BMIF was isolated from 60 patients including plasma cell dyscrasias (PCD, n = 33), other primary hematologic disorders (OHD, n = 15), and patients with secondary or nonhemtologic disorders (NHD, n = 12) and analyzed for an array of chemical constit...

journal_title：Hematological oncology

authors： Krashin E,Ellis M,Cohen K,Viner M,Neumark E,Rashid G,Ashur-Fabian O

更新日期：2018-04-01 00:00:00

abstract：:There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified t...

journal_title：Hematological oncology

authors： Wang B,Ren C,Zhang W,Ma X,Xia B,Sheng Z

更新日期：2013-03-01 00:00:00

abstract：:The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imagin...

journal_title：Hematological oncology

authors： Albano D,Bruno A,Patti C,Micci G,Midiri M,Tarella C,Galia M

更新日期：2020-02-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R-CHOP. The current 5-year overall survival is 60% to 70% using standard frontline therapy. However, the use of doxorubicin and its cardiotoxicity is a major clinical problem and preexisting cardiac disease may...

journal_title：Hematological oncology

authors： Prusila REI,Peroja P,Jantunen E,Turpeenniemi-Hujanen T,Kuittinen O

更新日期：2019-04-01 00:00:00

abstract：:Multiple myeloma, which is a monoclonal plasma cell malignancy, still remains incurable despite recent progress in our understanding of this disorder. Adoptive immunotherapy of multiple myeloma using cytokine-induced killer cells is yielding promising results in clinical trials; however, some myeloma cells still evade...

journal_title：Hematological oncology

authors： Nwangwu CA,Weiher H,Schmidt-Wolf IGH

更新日期：2017-12-01 00:00:00

abstract：:The expression of two membrane antigens identified by the monoclonal antibodies (McAb) My9 and 3C5 has been investigated in cells from 80 acute leukemias. My9 was positive in the blasts of 33 out of the 38 (87 per cent) cases of acute myeloid leukemia (AML) tested, regardless of FAB subtype, and in 13 of 18 (72 per ce...

journal_title：Hematological oncology

authors： Matutes E,Rodriguez B,Polli N,Tavares de Castro J,Parreira A,Andrews C,Griffin JD,Tindle RW,Catovsky D

更新日期：1985-07-01 00:00:00

abstract：:Mucosa-associated lymphoid tissue (MALT) lymphoma is a radiosensitive malignancy. We report on a case of severe retinopathy following radiation therapy with a moderate dose for orbital MALT lymphoma. A 69-year-old woman with orbital MALT lymphoma received definitive radiation therapy with a total dose of 36 Gy in 18 f...

journal_title：Hematological oncology

authors： Hata M,Kaneko A,Tomita N,Inoue T

更新日期：2014-12-01 00:00:00

abstract：:Acute myeloid leukaemia is a disease with unfavourable prognosis. The significance of various prognostic parameters is not fully understood. We studied 293 patients to examine the influence of ethnicity and molecular markers. The median survival for all patients was correlated with age, white blood cell count and kary...

journal_title：Hematological oncology

authors： Goldschmidt N,Cohen SB,Gatt ME,Safrai M,Rund D

更新日期：2014-06-01 00:00:00

abstract：:During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the major breakpoint cluster region of the BCR gene (M-bcr). Minor and micro breakpoint cluster regions (m-bcr with e1a2 transcript and micro-bcr with e19...

journal_title：Hematological oncology

authors： Andrikovics H,Nahajevszky S,Szilvási A,Bors A,Adám E,Kozma A,Kajtár B,Barta A,Poros A,Tordai A

更新日期：2007-09-01 00:00:00

abstract：:This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...

journal_title：Hematological oncology

authors： Barnes JA,Redd R,Fisher DC,Hochberg EP,Takvorian T,Neuberg D,Jacobsen E,Abramson JS

更新日期：2018-10-01 00:00:00